StreetAlpha.app
Home › Stocks › ARQT

Arcutis Biotherapeutics, Inc. (ARQT)

Healthcare
$27.33
▲ +0.66%
LAST CLOSE · NOV 17

Arcutis Biotherapeutics develops and sells ZORYVE topical treatments for psoriasis, atopic dermatitis, and seborrheic dermatitis. It last closed at $27.33 on Nov 17, up 0.66% on the day. The average 12-month price target from 3 analysts is $44.00 (+61.0% from the last close), with a high of $48.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ARQT, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is ARQT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$508.7M
+60.0% vs a year ago
Net income
$29.9M
5.9% margin
EPS (diluted)
$0.22
Free cash flow
$59.7M
11.7% margin
Valuation
Market cap
$3.5B
126.5M shares
P/E
124.2
Price over 12 month EPS
Price to sales
6.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$33.4M
At Sep 30
Debt
$109.4M
At Sep 30
Shareholder equity
$244.0M
Shares outstanding
126.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $3.7M$3.7MFY2022FY2023: $59.6M$59.6MFY2023FY2024: $196.5M$196.5MFY2024FY2025: $376.1M$376.1MFY2025

From ARQT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ARQT in the past 90 days
Average 12-month target
$44.00
▲ 61.0% upside

Based on 3 analysts who set a price target on ARQT in the past 90 days. The average target is $44.00, with a high of $48.00 and a low of $40.00, compared with the last close of $27.33.

Low $40.00Avg $44.00High $48.00
Blue marker: last close $27.33
Highest target$48.00
Average target$44.00
Lowest target$40.00
Latest rating changes
TD CowenMaintained
Nov 5Buy$40
GuggenheimTarget raised
Oct 19Buy$38 → $44
Cantor FitzgeraldInitiated
Oct 15Buy$48
Morgan StanleyMaintained
Aug 6Buy$38
GuggenheimMaintained
Aug 6Buy$38
DateFirmActionRatingPrice target
Nov 5TD CowenMaintainedBuy$40
Oct 19GuggenheimTarget raisedBuy$38 → $44
Oct 15Cantor FitzgeraldInitiatedBuy$48
Aug 6Morgan StanleyMaintainedBuy$38
Aug 6GuggenheimMaintainedBuy$38
Loading…

Technical Analysis

ARQT · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 9% below its 20 day and 1% below its 50 day average. It is 7% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 46). The nearest support is the Pivot at $27.25, and the nearest resistance the swing high (Sep 29) at $27.64.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 6.0%/day
Key levels
$34.5952 week high+26.6%
$29.8220 day average+9.1%
$27.67Pivot R1+1.2%
$27.6650 day average+1.2%
$27.64Swing high (Sep 29)+1.1%
$27.33Last close
$27.25Pivot−0.3%
$26.99100 day average−1.2%
$26.92Pivot S1−1.5%
$26.78Swing low (Jul 24)−2.0%
$25.40200 day average−7.1%
$19.3052 week low−29.4%
Indicators
RSI (14)45.58Middle of its rangeNeutral
MACD-0.29Below its signal lineBearish
Stochastic25.1Middle of its rangeNeutral
ADX (14)21.4Weak trend
Williams %R-77.6Oversold below −80, overbought above −20Neutral
CCI (20)-72.9Oversold below −100, overbought above 100Neutral
Rate of change−14.6%Change over 10 sessionsBearish
ATR (14)$1.64Typical daily range, 6.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for ARQT

What happened before

See how ARQT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ARQT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARQT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Sep 22 – Oct 16
Loading…

See today’s whale options flow across the market →

ARQT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲183 buying vs 112 selling
  • ▲Held by funds +13.9 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding293273+7.3%
In funds' top 1065+20.0%
Held by funds117.8%104.0%+13.9 pts
New / increased61 / 12240 / 95+35.6%
Reduced / sold out70 / 42101 / 38−19.4%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARQT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARQT is in one of them and how their past ARQT trades turned out.

ARQT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARQT in an article yet. Here's the latest on the wider market.

ARQT Congress Trades

All congress trades →
Trades, 12 months
3
Buys
2
67%
Sells
1
33%
People
1
Last filed Jun 8
Who traded ARQT · since 2022
Latest 5 filings of 6
$1K – $15KTraded May 29, 2026Filed Jun 8, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
$1K – $15KTraded Sep 15, 2023Filed Oct 15, 2023
$1K – $15KTraded Apr 17, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KMay 29, 2026Jun 8, 202610 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CASell (partial)$1K – $15KDec 11, 2025Jan 12, 202632 d
Josh GottheimerD · NJSell$1K – $15KSep 15, 2023Oct 15, 202330 d
Josh GottheimerD · NJBuy$1K – $15KApr 17, 2023May 19, 202332 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a biopharmaceutical company based in Westlake Village, California. It develops and sells treatments for skin conditions, mainly its ZORYVE line of topical creams and foam. These products treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in children and adults. Its customers include dermatologists, primary care practitioners, and pediatricians who prescribe them.

Headquarters
Westlake Village, CA